Survival curve of the studying IEI cohort who underwent allogeneic HCT alongside RTC with alemtuzumab (IMAGE)

Tokyo Medical and Dental University

Survival curve of the studying IEI cohort who underwent allogeneic HCT alongside RTC with alemtuzumab

Caption

 The OS and GEFS of the study cohort. The solid line and the dashed line show OS and GEFS curves, respectively. OS and GEFS at 2 years post-HCT are described with 95% confidence intervals in brackets. Grade III–IV acute GVHD, systemically treated chronic GVHD, second transplantation, and death were defined as failure events for GEFS. OS, overall survival; GEFS, graft-versus-host disease-free, event-free survival.

Credit

Department of Child Health and Development, TMDU

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.